MAM
TGTX icon

Marquette Asset Management’s TG Therapeutics TGTX Stock Holding History

Marquette Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69K Hold
49
– – ﹤0.01% 538
2026
Q1 		$1.63K Buy
+49
New +$1.46K ﹤0.01% 592

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Marquette Asset Management's TGTX Position: Q2 2026 in Review

Marquette Asset Management held its TG Therapeutics (TGTX) position steady in Q2 2026 at 49 shares worth $2.69K. The position accounts for ﹤0.01% of the portfolio, ranked #538.

Marquette Asset Management first reported a position in TGTX in Q1 2026 and has held it in 2 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Marquette Asset Management held 49 shares of TG Therapeutics worth $2.69K as of Q2 2026.
  • Marquette Asset Management left its TG Therapeutics share count unchanged in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Marquette Asset Management's portfolio in Q2 2026, its #538 holding.
  • Marquette Asset Management first reported a position in TG Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.